Table 3. IC₅₀ Values for LasR Inhibition by Library Members in E. coli JLD271 (pJN105L, pSC11)^a.

compound	IC50 (μM)b	95% CI (μM)	max. inhibition (%)c
2 (OOHL)d	0.078	0.032–0.19	35
3 (OHHL)d	10.4	5.3–21	70
4e	2.8	1.1–6.8	65
5	2.8	1.3–6	65
6d	1.0	0.34–3.2	70
7d	3.5	2.6–4.8	75
8d	0.16	0.043–0.57	45
9	agonist	–	N/A
10 (CL)d	0.49	0.1–2.3	40
11 (ITC-12)	agonist	–	N/A
12	–	–	N/A
13	4.7	1.9–12	40
14	agonist	–	N/A
15	agonist	–	N/A
16 (mBTL)	agonist	–	N/A
17 (C10-CPA)	–	–	N/A
18 (V-06-018)e	2.3	0.89–6.1	50
19 (TP-1)	agonist	–	N/A
20 (TP-5)e,f	70	56–88	85
21 (C-30)g	–	–	N/A
22 (PD-12)	–	–	N/A

^aAntagonism dose–response assays were performed for each compound in the presence of 2 nM OdDHL.

^bCompounds labeled as “agonist” showed LasR-modulatory activity only at levels ≥100% (the LasR activation level of OdDHL at 2 nM).

^cDenotes the largest amount of LasR inhibition seen for each compound at any concentration within the dose–response assay. For the full inhibition trace, see Figure S3.

^d,e,f,gSee Table 1 footnotes.